Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.54 |
| ▸ | KLK7 | P49862 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 3/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7408256 | 1.00 | KLK5 (0.54) | KLK5KLK7CTSSCTSKCTSL | |
| SCHEMBL7403896 | 0.90 | KLK5 (0.52) | KLK5KLK7CTSSCTSKCTSL | |
| SCHEMBL7403898 | 0.90 | KLK5 (0.52) | KLK5KLK7CTSSCTSKCTSL | |
| SCHEMBL7294995 | 0.87 | CTSS (0.56) | KLK5KLK7CTSSCTSKCTSL | |
| SCHEMBL7460511 | 0.87 | KLK7 (0.49) | KLK5KLK7CTSSCTSKCTSL | |
| SCHEMBL7460520 | 0.87 | KLK7 (0.49) | KLK5KLK7CTSSCTSKCTSL | |
| SCHEMBL13669577 | 0.87 | CTSS (0.67) | CTSSCTSKCTSLCTSBATM | |
| SCHEMBL21269701 | 0.86 | KLK5 (0.60) | KLK5KLK7CTSSCTSKCTSL | |
| SCHEMBL27487264 | 0.86 | KLK5 (0.60) | KLK5KLK7CTSSCTSKCTSL | |
| SCHEMBL30375069 | 0.86 | KLK5 (0.60) | KLK5KLK7CTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495699-B2 | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | AGOURON PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | BENDER STEVEN L (US) | 2002-02-14 | — | — | US | disclosed |
| US-6306892-B1 | ENZYME INHIBITORS HETEROCYCLIC AMIDES | AGOURON PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6008243-A | AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0937042-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998017643-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | MMP9, MMP2, MMP3 | KLK5 194/4885KLK7 469/4885CTSS 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.